HTG Molecular Diagnostics, Inc.
HTGMQ
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 6.21M | 6.37M | 6.80M | 8.07M | 8.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.21M | 6.37M | 6.80M | 8.07M | 8.66M |
| Cost of Revenue | 11.34M | 11.36M | 11.69M | 12.03M | 11.42M |
| Gross Profit | -5.13M | -4.99M | -4.88M | -3.95M | -2.76M |
| SG&A Expenses | 14.46M | 15.84M | 17.72M | 18.55M | 18.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.91M | 27.30M | 29.53M | 30.68M | 29.67M |
| Operating Income | -19.69M | -20.93M | -22.73M | -22.61M | -21.02M |
| Income Before Tax | -20.14M | -21.58M | -22.08M | -22.06M | -18.77M |
| Income Tax Expenses | 12.70K | 10.90K | 8.70K | 9.00K | 20.40K |
| Earnings from Continuing Operations | -20.15 | -21.59 | -22.09 | -22.07 | -18.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.15M | -21.59M | -22.09M | -22.07M | -18.79M |
| EBIT | -19.69M | -20.93M | -22.73M | -22.61M | -21.02M |
| EBITDA | -19.20M | -20.35M | -22.09M | -21.91M | -20.31M |
| EPS Basic | -18.08 | -25.53 | -29.30 | -31.64 | -29.91 |
| Normalized Basic EPS | -11.36 | -16.01 | -19.81 | -21.27 | -22.12 |
| EPS Diluted | -18.08 | -25.53 | -29.30 | -31.64 | -29.91 |
| Normalized Diluted EPS | -11.36 | -16.01 | -19.81 | -21.27 | -22.12 |
| Average Basic Shares Outstanding | 5.10M | 3.55M | 3.14M | 2.83M | 2.48M |
| Average Diluted Shares Outstanding | 5.10M | 3.55M | 3.14M | 2.83M | 2.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |